Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Who May Be Eligible (Plain English)

DISEASE CHARACTERISTICS: - Meets one of the following criteria: - diagnosed by tissue sample (biopsy-confirmed) solid tumor or hematologic malignancy - Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging PATIENT CHARACTERISTICS: - Able to lie still in the PET scanner - Girth and weight must be suitable to enter the gantry - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: - Not specified Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
DISEASE CHARACTERISTICS: * Meets one of the following criteria: * Histologically confirmed solid tumor or hematologic malignancy * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging PATIENT CHARACTERISTICS: * Able to lie still in the PET scanner * Girth and weight must be suitable to enter the gantry * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * Not specified

Treatments Being Tested

DEVICE

3'-deoxy-3'-[18F]fluorothymidine

The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.

Locations (1)

Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States